Antibody–Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned

Abstract

Antibody–drug conjugates are an emerging class of biopharmaceuticals changing the landscape of targeted chemotherapy. These conjugates combine the target specificity of monoclonal antibodies with the anti-cancer activity of small-molecule therapeutics. Several antibody–drug conjugates have received approval for the treatment of various types of cancer including gemtuzumab ozogamicin (Mylotarg®), brentuximab vedotin (Adcetris®), trastuzumab emtansine (Kadcyla®), and inotuzumab ozogamicin, which recently received approval (Besponsa®). In addition to these approved therapies, there are many antibody–drug conjugates in the drug development pipeline and in clinical trials, although these fall outside the scope of this article. Understanding the pharmacokinetics and pharmacodynamics of antibody–drug conjugates and the development of pharmacokinetic/pharmacodynamic models is indispensable, albeit challenging as there are many parameters to incorporate including the disposition of the intact antibody–drug conjugate complex, the antibody, and the drug agents following their dissociation in the body. In this review, we discuss how antibody–drug conjugates progressed over time, the challenges in their development, and how our understanding of their pharmacokinetics/pharmacodynamics led to greater strides towards successful targeted therapy programs.

Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma

“…As such, a central focus of future investigations will be the verification and exploration of the mechanisms by which NP-BCMA may be renally cleared, which is a result that is inconsistent with previous literature. 46,47 It should be noted that our experimental constructs introduce features of potential clinical novelty that bypass many of the limitations seen with other diagnostic agents used for the detection of MM. For instance, unlike with experimental immunoconjugates that are employed with PET/CT, our constructs are not reliant upon ionizing radiation and may enable longitudinal administration to the same subject.…”

MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors

“…Currently there are four ADCs approved for clinical use (5). However, there remains an unmet need for effective therapies in many patient populations.…”

A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists

“…Antibody-drug conjugates (ADCs) have emerged as an important class of anticancer therapeutics (Hedrich et al 2018). They are designed to deliver highly cytotoxic small molecules directly to cancer cells via tumor-specific antibodies, hence providing a much wider therapeutic window than conventional chemotherapy.…”